Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Cash & Equivalents: 2018-2021

Historic Cash & Equivalents for Pharming Group N.V (PHAR) over the last 4 years, with Dec 2021 value amounting to $200,391.

  • Pharming Group N.V's Cash & Equivalents fell 44.71% to $105.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $105.0 million, marking a year-over-year decrease of 44.71%. This contributed to the annual value of $200,391 for FY2021, which is 99.90% down from last year.
  • Latest data reveals that Pharming Group N.V reported Cash & Equivalents of $200,391 as of FY2021, which was down 99.90% from $205.2 million recorded in FY2020.
  • Pharming Group N.V's 5-year Cash & Equivalents high stood at $205.2 million for FY2020, and its period low was $200,391 during FY2021.
  • In the last 3 years, Pharming Group N.V's Cash & Equivalents had a median value of $74.3 million in 2019 and averaged $93.2 million.
  • Per our database at Business Quant, Pharming Group N.V's Cash & Equivalents surged by 175.94% in 2020 and then slumped by 99.90% in 2021.
  • Over the past 4 years, Pharming Group N.V's Cash & Equivalents (Yearly) stood at $94.9 million in 2018, then fell by 21.63% to $74.3 million in 2019, then skyrocketed by 175.94% to $205.2 million in 2020, then plummeted by 99.90% to $200,391 in 2021.